Anika Therapeutics
ANIK
139 hedge funds and large institutions have $569M invested in Anika Therapeutics in 2021 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 21 closing their positions.
5% more capital invested
Capital invested by funds: $543M → $569M (+$26.1M)
4% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 49
1.53% less ownership
Funds ownership: 92.89% → 91.36% (-1.5%)
4% less funds holding
Funds holding: 145 → 139 (-6)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
+$9.72M |
| 2 |
Janus Henderson Group
London,
|
+$8.72M |
| 3 |
TI
Trigran Investments
Northbrook,
Illinois
|
+$7.85M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.68M |
| 5 |
PGM
Parian Global Management
Pound Ridge,
New York
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$15.3M |
| 2 |
Natixis Advisors
Boston,
Massachusetts
|
-$7.33M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$4.79M |
| 4 |
Morgan Stanley
New York
|
-$3.81M |
| 5 |
Millennium Management
New York
|
-$3.36M |
ANIK Hedge Fund Activity: Q2 2021 in Review
139 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2021, worth a combined $569M — up 4.8% from $543M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ANIK and 17 opened new positions — a net loss of 4 holders — while 49 trimmed existing stakes and 47 added.
The largest buyer was Kayne Anderson Rudnick Investment Management, adding an estimated $9.72M. The largest seller was Boston Trust Walden, exiting entirely with an estimated $15.3M sold.
- 139 institutional investors held Anika Therapeutics (ANIK) as of Q2 2021, down from 145 in Q1 2021.
- Funds reported $569M of Anika Therapeutics stock for Q2 2021, up 4.8% quarter-over-quarter.
- 17 funds opened new Anika Therapeutics positions in Q2 2021 and 21 closed out, a net change of -4 holders.
- The largest Anika Therapeutics buyer in Q2 2021 was Kayne Anderson Rudnick Investment Management, an estimated $9.72M added.
- The largest Anika Therapeutics seller in Q2 2021 was Boston Trust Walden, an estimated $15.3M sold.
Based on aggregated 13F filings for Q2 2021.